Device Trial Radar · NCT04061733
New Hydroxyethyl Cellulose Hydrogel for the Treatment of the Pain of Knee Arthrosis
Last checked: Nov 20, 2026Latest source record: Dec 29, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
50
Actual
Start
Sep 30, 2019
Primary completion
Jul 31, 2023
Study completion Jul 31, 2024
Sponsor
- Lead sponsor
- PromedonNot on our public-company list
- Sponsor type
- Industry
- First posted
- Aug 20, 2019
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 40 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Prospective, multicenter study, unmasked, single-arm, to study the safety and efficacy of a new hydroxyethyl cellulose hydrogel for the treatment of the knee pain caused by osteoarthritis.
Conditions
- Osteoarthritis, Knee
- Pain
Interventions
Hydrogel injectionDevice
Hydrogel injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pain assessment: Percentage of pain reduction using a visual analogue scaleTime frame: Change from Baseline at postoperative 12 months follow-up
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
CEMIC
Buenos Aires, Argentina
DOM Centro de Reumatología
Buenos Aires, Argentina
IADT
Buenos Aires, Argentina
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.